---
title: "Clinitech Laboratory Ltd (544220) — Share Price, Financials & Analysis"
symbol: "544220"
company: "Clinitech Laboratory Ltd"
canonical: "https://tapetide.com/stocks/544220"
isin: "INE0QMR01015"
nse_symbol: "CLINITECHLABORATORYLTD"
bse_code: "544220"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 8
generated_at: "2026-09-13T19:17:09.083Z"
---

# Clinitech Laboratory Ltd (544220)

Canonical page: https://tapetide.com/stocks/544220

## Company

- **NSE Symbol:** CLINITECHLABORATORYLTD
- **BSE Code:** 544220
- **ISIN:** INE0QMR01015
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-08-01
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** ctllab.in

## About

Incorporated in 1990, Clinitech Laboratory Ltd is in the business of providing pathology and related healthcare services.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:42:30.623807Z.

- **Market Cap:** ₹8 Cr
- **Classification:** SME
- **P/E (reported):** 19.3
- **EPS (reported):** ₹1.59
- **Book Value:** ₹40.52
- **Price to Book:** 0.87
- **Dividend Yield:** 0%
- **ROE:** 4.48%
- **ROCE:** 6.62%
- **Debt to Equity:** 0.04
- **Revenue (yearly):** ₹9.7 Cr
- **Net Income:** ₹0.4 Cr
- **EBITDA:** ₹1.2 Cr
- **52-Week High:** ₹51.78
- **52-Week Low:** ₹28.55
- **RSI (14):** 13.92

## Key Insights

### Strengths

- Company is almost debt free.
- Stock is trading at 0.87 times its book value
- Promoter holding has increased by 1.79% over last quarter.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.94% over last 3 years.
- Debtor days have increased from 57.9 to 71.2 days.
- Working capital days have increased from 99.9 days to 164 days

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 10.23% | -104.41% | 10.23% |
| ebitda margin growth | -2.96% | — | — |
| net income growth | 0% | -12% | 3% |
| revenue growth | 14.12% | 14% | 16% |
| roce | -1.93% | — | — |
| roe | 0.22% | — | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 3.06 | 3.34 | 4.08 | 4.16 | 5.08 | 4.39 |
| Expenses | 2.78 | 2.61 | 3.52 | 3.88 | 4.54 | 3.94 |
| Operating Profit | 0.28 | 0.73 | 0.56 | 0.28 | 0.54 | 0.45 |
| OPM % | 9.15 | 21.86 | 13.73 | 6.73 | 10.63 | 10.25 |
| Other Income | 0.02 | 0.01 | 0.05 | 0.17 | 0.11 | 0.08 |
| Interest | 0.04 | 0.06 | 0.04 | 0.02 | 0.05 | 0.02 |
| Depreciation | 0.19 | 0.25 | 0.31 | 0.14 | 0.25 | 0.26 |
| Profit before tax | 0.07 | 0.43 | 0.26 | 0.29 | 0.35 | 0.25 |
| Tax % | 14.29 | 30.23 | 15.38 | 41.38 | 14.29 | 52 |
| Net Profit | 0.07 | 0.3 | 0.22 | 0.17 | 0.3 | 0.12 |
| EPS in Rs | 0.47 | 1.79 | 0.96 | 0.74 | 1.31 | 0.53 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 4.55 | 6.38 | 6.35 | 6.4 | 8.23 | 9.48 |
| Expenses | 3.72 | 5.31 | 4.99 | 5.41 | 7.4 | 8.49 |
| Operating Profit | 0.83 | 1.07 | 1.36 | 0.99 | 0.83 | 0.99 |
| OPM % | 18.24 | 16.77 | 21.42 | 15.47 | 10.09 | 10.44 |
| Other Income | 0.04 | 0.07 | 0.02 | 0.04 | 0.23 | 0.19 |
| Interest | 0.08 | 0.06 | 0.07 | 0.09 | 0.06 | 0.07 |
| Depreciation | 0.25 | 0.38 | 0.45 | 0.44 | 0.45 | 0.51 |
| Profit before tax | 0.54 | 0.7 | 0.86 | 0.5 | 0.55 | 0.6 |
| Tax % | 25.93 | 27.14 | 29.07 | 26 | 29.09 | 30 |
| Net Profit | 0.4 | 0.51 | 0.61 | 0.37 | 0.39 | 0.42 |
| EPS in Rs | 6 | 3.4 | 4.07 | 2.2 | 1.71 | 1.84 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.67 | 1.5 | 1.5 | 1.68 | 2.28 | 2.28 |
| Reserves | 0.72 | 0.35 | 0.88 | 1.87 | 6.55 | 6.97 |
| Borrowings | 0.54 | 0.89 | 1.03 | 0.87 | 0 | 0.36 |
| Other Liabilities | 0.8 | 0.94 | 2.62 | 1.19 | 2.01 | 1.3 |
| Total Liabilities | 2.73 | 3.68 | 6.03 | 5.61 | 10.84 | 10.91 |
| Fixed Assets | 0.84 | 1.65 | 1.33 | 1.71 | 2.12 | 2.18 |
| CWIP | 0.08 | 0.41 | 0.56 | 0.94 | 1.01 | 0.99 |
| Investments | 0.09 | 0.14 | 2.02 | 0.07 | 0.07 | 0.08 |
| Other Assets | 1.72 | 1.48 | 2.12 | 2.89 | 7.64 | 7.66 |
| Total Assets | 2.73 | 3.68 | 6.03 | 5.61 | 10.84 | 10.91 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0.38 | 0.96 | 1.25 | -1.28 | -0.88 | -0.9 |
| Cash from Investing Activity | 0.54 | -1.47 | -0.65 | 0.75 | -0.73 | -0.44 |
| Cash from Financing Activity | -0.88 | 0.29 | 0.09 | 0.45 | 3.98 | 0.33 |
| Net Cash Flow | 0.04 | -0.22 | 0.68 | -0.08 | 2.37 | -1.01 |
| Free Cash Flow | 0.19 | -0.55 | 0.97 | -2.49 | -1.73 | -1.45 |
| CFO/OP | 64 | 109 | 114 | -115 | -87 | -70 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 44.92 | 20.6 | 28.17 | 34.22 | 68.3 | 71.23 |
| Inventory Days | 32.21 | 40.28 | 43.68 | 92.91 | — | — |
| Days Payable | 164.61 | 130.9 | 124.79 | 116.14 | — | — |
| Cash Conversion Cycle | -87.48 | -70.03 | -52.95 | 10.99 | 68.3 | 71.23 |
| Working Capital Days | 43.32 | -4.58 | -33.34 | 21.67 | 114.42 | 163.63 |
| ROCE % | — | 32.55 | 30.24 | 14.81 | 8.15 | 7.27 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Promoters | 61.58% | 61.58% | 62.42% | 64.2% |
| FIIs | 0.32% | 0.32% | 0.32% | 0.32% |
| DIIs | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% |
| Public | 35.91% | 36.28% | 35.91% | 34.17% |
| Others | 2.2% | 1.83% | 1.36% | 1.31% |
| No. of Shareholders | 346 | 303 | 303 | 297 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 4 / 3 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 37.92 | Sell |
| EMA (10) | 37.35 | Sell |
| SMA (20) | 39.55 | Sell |
| EMA (20) | 38.44 | Sell |
| SMA (50) | 38.93 | Sell |
| EMA (50) | 39.31 | Sell |
| SMA (100) | 40.94 | Sell |
| EMA (100) | 41.49 | Sell |
| SMA (200) | 46.57 | Sell |
| EMA (200) | 50.66 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 40.2 | Neutral |
| MACD (12,26,9) | -1.03 | Sell |
| Stochastic (14,3,3) | 5.38 | Buy |
| ADX (14) | 11.14 | Neutral |
| Williams %R (14) | -98.97 | Buy |
| ATR (14) | 1.55 | High Volatility |
| ROC (12) | -12.25 | Sell |
| Stoch RSI (14) | 11.24 | Buy |
| UO (7,14,28) | 22.85 | Buy |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-24 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8a005ef-fcf2-49ad-b067-4945e85be4fe.pdf) |
| 2026-08-22 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e0a9dfe-5e20-40e1-b7dd-e16a660f7b91.pdf) |
| 2026-08-22 | [Fixes Book Closure Date For 16Th AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d670a500-ee32-4006-ac40-de1146e24376.pdf) |
| 2026-08-22 | [Annual General Meeting To Be Held On September 24 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2eb78886-5583-49b7-824a-2dbc02569ffc.pdf) |
| 2026-08-17 | [Board Meeting Outcome for Outcome Of Board Meeting Held Today On Monday August 17 2026 At 11.30 A.M (IST) Through Video Conferencing](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85f07034-fdf9-4154-826f-a80b2e1556ba.pdf) |
| 2026-08-12 | [Board Meeting Intimation for Board Meeting To Be Held On Monday August 17 2026 Through Video Conferencing At 11.30 A.M (IST).](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44393de9-ac71-4ed2-8dfc-6395d34816a8.pdf) |
| 2026-07-07 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f882bc5-164d-4947-94ba-b9599b14987b.pdf) |
| 2026-05-28 | [Board Meeting Outcome for Outcome Of Board Meeting Held For FY 2026-27 Today I.E May 28 2026 Through Video Conferencing At 02.30 P.M](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39f897ec-a7d2-48b8-8385-b74e785e7fb9.pdf) |
| 2026-05-28 | [Statement Of Deviation & Variation As On March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ffaefa9-3e9e-480c-9ca9-194274aaffdd.pdf) |
| 2026-05-22 | [Board Meeting Intimation for Board Meeting For FY 2026-27 To Be Held On Thrusday May 28 2026 At 02.30 P.M Through Video Conferencing](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f04cd72-e5ea-4da7-a9f0-c4d47238fb6f.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-28 | [Results- Financial Results For Half Year And Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cef45d7a-5c29-4712-b166-603d57b960d1.pdf) |
| 2025-11-12 | [Financials Results For 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49f2e73f-4aa2-4478-9461-b0c5d72aee21.pdf) |
| 2025-05-23 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Friday May 23 2025 At 11.30 AM For Approval Of Financial Results As On March 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ef1ffb0-2c82-4d9c-bff4-09888be28603.pdf) |
| 2025-05-23 | [Financial Results For 31.03.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4eae5d0-a8bf-41ca-b9ba-9baa551990a1.pdf) |
| 2024-11-13 | [Outcome Of The Board Meeting Held On Wednesday, November 13, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f609dcb4-833a-4e8b-b30c-31afbffbefdb.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Clinitech Laboratory signed an MOU with MD Plus Multispeciality Clinic for pathology lab and referral radiology services. | [General Update W.R.T Memorandum Of Understanding ("MOU") 9h - Clinitech Laboratory signed an MOU with MD Plus Multispeciality Clinic for pathology lab and referral radiology services.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ca5dfccf-477e-44f0-a5e8-37f1774548e7.pdf) |
| 9 Jan - Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended December 31, 2025 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jan - Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b651b14d-ebbb-462e-a4bb-a5c4c7c6fd72.pdf) |
| 9 Apr - Clinitech Laboratory changed market maker to Kalpalabdhi Financials effective April 10, 2026. | [General Update Under Reg 30 Of SEBI (LODR) Regulations For Change In Market Maker 9 Apr - Clinitech Laboratory changed market maker to Kalpalabdhi Financials effective April 10, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6e21ce34-0d85-430e-a4fb-50718e8e89ae.pdf) |
| 7 Apr - Certificate under REg 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Certificate under REg 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9fa658b5-3413-4373-a716-1fa84c52887e.pdf) |
| 6 Feb - Board approved Analog IVD Solutions Pvt Ltd subsidiary; INR 22.50 lakh Bank of Baroda term loan. | [Board Meeting Outcome for Outcome Of 09Th Board Meeting Held Today At Its Registered Office 6 Feb - Board approved Analog IVD Solutions Pvt Ltd subsidiary; INR 22.50 lakh Bank of Baroda term loan.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/30d367c3-6a5b-438d-88e8-0217dd81dc2a.pdf) |
| 6 Apr - Yearly Regulation 31(4) disclosure received from promoter and promoter group for FY ended March 31, 2026. | [General Update W.R.T Receipt Of Letter From Promoter Under Reg 31(4) Of SEBI (SAST) Regulations For The Year Ended March 31, 2026 6 Apr - Yearly Regulation 31(4) disclosure received from promoter and promoter group for FY ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/00458bcb-c98d-40f2-86af-21ce8b671b55.pdf) |
| 5 Feb - Board meeting Feb 14, 2026 to approve Q3 and nine-month results; trading window closed from Jan 1. | [Board Meeting Intimation for Please Find Attached The Intimation For Board Meeting Of The Company To Be Held On 14Th February, 2026 5 Feb - Board meeting Feb 14, 2026 to approve Q3 and nine-month results; trading window closed from Jan 1.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0127e568-1e12-48a1-8240-8fad3340c342.pdf) |
| 30 Mar - Promoter purchased 1,200 shares on March 27, 2026; holding rose to 64.20%. | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Mar - Promoter purchased 1,200 shares on March 27, 2026; holding rose to 64.20%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/348F9C32_C58F_4D98_A714_1AFD8D1CDB17_123202.pdf) |
| 27 Jan - Board on Jan 27, 2026 approved subsidiary formation and reconstituted ICC; POSH policy revised. | [Board Meeting Outcome for Outcome Of 08Th Board Meeting For FY 2025-26 Thorugh Video Conferencing 27 Jan - Board on Jan 27, 2026 approved subsidiary formation and reconstituted ICC; POSH policy revised.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/218bb1a9-d2b4-410e-808a-741150f1477d.pdf) |
| 27 Apr - Clinitech Laboratory confirms it is not a Large Corporate under SEBI circular. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 27 Apr - Clinitech Laboratory confirms it is not a Large Corporate under SEBI circular.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d5496ca0-8f58-4db4-97f1-11b31746b1d1.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2012 from nse](https://archives.nseindia.com/annual_reports/AR_SADBHAV_2011_2012_18092012112203.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/39158a1f-67ce-47ec-8baf-ca9ab8c24579.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4d720e99-8251-41b0-ba83-f29c2470333e.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56bbb456-1c46-4326-850d-138e09974b5b.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2abf3636-2616-4ef9-98ef-b0e449fc0fb7.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532710/77086532710.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532710/71862532710.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532710/66685532710.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532710/5327100319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532710/5327100318.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2016 | [Concall - Sep 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2AF0361B_3C24_445D_A026_D91D3E27EC1D_125151.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:17:09.083Z.